Thompson Davis & Co’s Veracyte VCYT Stock Holding History

Thompson Davis & Co’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,500	Closed	-$14K	–	1182
2017 Q1	$14K	Buy	+1,500	New	+$12.3K	0.02%	611

Other funds holding VCYT

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Thompson Davis & Co's VCYT Position: Q2 2017 in Review

Thompson Davis & Co sold out of Veracyte (VCYT) in Q2 2017, closing a stake of 1,500 shares — an estimated $14K sold.

Thompson Davis & Co first reported a position in VCYT in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 88 funds tracked by Wall St. Rank hold VCYT as of Q2 2017.

Thompson Davis & Co reported no remaining Veracyte position as of Q2 2017 after selling out during the quarter.
Thompson Davis & Co sold 1,500 Veracyte shares in Q2 2017, an estimated $14K.
Thompson Davis & Co first reported a position in Veracyte in Q1 2017 and held it in 1 quarter.
Thompson Davis & Co's Veracyte position peaked at $14K in Q1 2017.
88 funds tracked by Wall St. Rank held Veracyte as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.